Welcome to BioSeeker Group!

MicroRNAs in Cancer Drug Pipeline Update

Additional Information

Published Date Aug 4, 2016
Format Desktop App plus Online Access to Updates (One Year)
Publisher BioSeeker Group
Product Line View All Available Drug Pipeline Update Reports

Availability: In stock

$2,250.00

Quick Overview

BioSeeker Group have identified 567 companies plus partners who are today developing 841 microRNA targeting and competitor drugs in 3023 developmental projects in cancer across 289 different targets. In addition, there are 5 suspended drugs and another 343 drugs where development has been ceased.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to MicroRNAs in Cancer Drug Pipeline Update.

    To find out more about MicroRNAs in Cancer Drug Pipeline Update, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that MicroRNAs in Cancer Drug Pipeline Update is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or
Extra value: One year of free online updates included with this product

Executive Summary

BioSeeker Group have identified 567 companies plus partners who are today developing 841 microRNA targeting and competitor drugs in 3023 developmental projects in cancer across 289 different targets. In addition, there are 5 suspended drugs and another 343 drugs where development has been ceased.

For busy executives within Pharma, Biotech and Investment companies who know they need to stay on top of the developmental environment in their field, we offer the Drug Pipeline update series.

You get detailed, world-wide drug pipeline information, delivered in an unbiased and independent pipeline progress analysis for each identified drug.

Buying the MicroRNAs in Cancer Drug Pipeline Update will mean you have this important data at your fingertips and ensure that you can:

* Show investors/board/management that you are right on top of drug development progress in your therapeutic area.
* Find competitors, collaborations partners, M&A candidates etc. and track them by their products.
* Jump start competitive drug intelligence operations
* Benchmark your own development against world wide data
* Compare portfolio and therapy focus with your peers
* Speed up pro-active in-/outlicensing strategy work

Our software lets you define your selectivity in each drug search with up to 24 different drug specific parameters. Each parameter has multi-select options to them and can be used as either an inclusion parameter or exclusion parameter.


The following short video playlist demonstrates the use of the filter sections, how you can make an inclusion and exclusion search and what to expect from a drug profile result.


Some facts about MicroRNAs in Cancer Drug Pipeline Update

The hot entry of microRNA (miRNA) targeting drugs in oncology may come to revolutionize how we in the near future can launch a highly tumor-specific, multi-targeted attack with minimal toxicities either as a monotherapy or perhaps even more likely in a combinatorial drug setting. miRNA may also hold great potential as biomarkers, albeit a lot of work is a head of us and the industry hasn't really caught up with the science yet in clinical trials as very few of them address the predictive capability of miRNAs.
In this Drug Pipeline Update about MicroRNAs in cancer, BioSeeker features drugs which stimulates, inhibits or regulates miRNA for the treatment of cancer, early miRNA biomarker evaluations in cancer and those drug targets which stands under control by known miRNAs. To complete the competitive landscape around miRNAs BioSeeker has also included all other competitor substances to known microRNAs targets. It is a true David versus Goliath situation and it all comes down to in which biological context targeting miRNAs is the smarter and safer choice? Consequently this product is a great tool for both those who could be facing competition from miRNAs and for miRNA developing companies to know other drugs targeting the same targets as their miRNAs.
There are today 567 companies plus partners developing 841 microRNA targeting and competitor drugs in 3023 developmental projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 343 drugs. Micrornas In Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 289 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 264 out of the 266 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 56 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.


Details from MicroRNAs in Cancer Drug Pipeline Update at a glance

This short overview shows actual findings from the MicroRNAs in Cancer Drug Pipeline Update report.

Companies Includes more than 567 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.

Note: You are able to sort and find drugs according to companies and partners from drop-down menus in the application. You may also sort and find drugs according to country of companies.
Drug name & Synonyms Lists commercial, generic and code names for drugs.
Developmental stage This Drug Pipeline Update contains 841 microRNA targeting and competitor drugs in development, which have a total of 3023 developmental projects in cancer. In addition there are suspended and ceased drugs.

Pipeline Breakdown According to Number of Drugs
Marketed# 57
Pre-registration# 8
Phase III# 90
Phase II# 238
Phase I# 312
Preclinical# 412
No Data# 29
Suspended# 5
Ceased# 343

Note: You are able to sort and find drugs according to developmental stage from drop-down menu in the application.
Indications Included microRNA targeting and competitor drugs are also in development for 275 other indications, where of 177 are different cancer indications.

Note: You are able to find and sort drugs according to type of indication from drop-down menu in the application.
Targets Mutations
All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers. To date 264 out of the 266 studied drug targets so far have been recorded with somatic mutations and the software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.

Biological Structures
The identity of available biological structures on 222 drug targets was retrieved from the RCSB Protein Databank for you to easily review the 4551 structures available today among drug targets.

Identified drugs are linked to more than 289 different targets, divided into 56 classifications of molecular function:
- Antigen binding
- ATPase activity
- Auxiliary transport protein activity
- Catalytic activity
- Cell adhesion molecule activity
- Chaperone activity
- Chemokine activity
- Chromatin binding
- Cysteine-type peptidase activity
- Cytokine activity
-
- Cytoskeletal protein binding
- Deacetylase activity
- Deaminase activity
- DNA binding
- DNA topoisomerase activity
- DNA-methyltransferase activity
- G-protein coupled receptor activity
- Growth factor activity
- GTPase activity
- Heat shock protein activity
- Isomerase activity
- Kinase activity
- Kinase binding
- Kinase regulator activity
- Ligase activity
- Lipid kinase activity
- Lipid phosphatase activity
- Metallopeptidase activity
- Molecular function unknown
- Motor activity
- Oxidoreductase activity
- Peroxidase activity
- Protease inhibitor activity
- Protein binding
- Protein serine/threonine kinase activity
- Protein threonine/tyrosine kinase activity
- Protein tyrosine/serine/threonine phosphatase activity
- Protein-tyrosine kinase activity
- Receptor activity
- Receptor binding
- Receptor signaling complex scaffold activity
- Receptor signaling protein tyrosine phosphatase activity
- RNA-directed DNA polymerase activity
- Serine-type peptidase activity
- Structural constituent of cytoskeleton
- Structural molecule activity
- Superoxide dismutase activity
- T cell receptor binding
- Transcription factor activity
- Transcription regulator activity
- Transferase activity
- Translation regulator activity
- Transmembrane receptor activity
- Transmembrane receptor protein tyrosine kinase activity
- Transporter activity
- Ubiquitin-specific protease activity

Sub-Cellular Localization
Identified targets are categorized into 33 different primary and alternate sub-cellular localizations:
- Basolateral membrane
- Cell junction
- Centrosome
- Chromosome
- Clathrin-coated vesicle
- Cytoplasm
- Cytoplasmic vesicle
- Cytoskeleton
- Cytosol
- Endoplasmic reticulum
- Endosome
- Extracellular
- Golgi apparatus
- Golgi membrane
- Integral to membrane
- Intermediate filament
- Kinetochore
- Lysosome
- Membrane fraction
- Microtubule
- Mitochondrial membrane
- Mitochondrion
- Nuclear membrane
- Nucleolus
- Nucleoplasm
- Nucleus
- Perinuclear region
- Perinuclear vesicle
- Peroxisome
- Plasma membrane
- Sarcoplasmic reticulum
- Secreted
- Vesicle

Note: You are able to find and sort drugs according to target gene name, protein name, molecular function of target, target localization, presence of mutations and availability of biological structures of target from drop-down menus in the application.
Target Expression Profile Direct links are provided from inside the application to 420 protein expression profiles of 251 drug targets in various human tissues and cancer types, cell lines and primary cells, including up to:
- 48 different normal tissue types
- 20 different types of cancer
- 47 cell lines
- 12 samples of primary blood cells
Pathway Referals Identified targets have been cross referenced against their involvement in different cellular pathways, according to BioCarta, KEGG, NCI-Nature and NetPath.
- BioCarta# 243 Pathways
- KEGG# 185 Pathways
- NCI-Nature# 255 Pathways
- NetPath# 32 Pathways

Note: You are able to find and sort drugs according to targeted pathways from drop-down menus in the application.
Mechanism In total there are different drug mechanism of action represented in this Drug Pipeline Update.

Note: You are able to find and sort drugs according to mechanism of action from drop-down menu in the application.
Compound Identified drug compounds are described by:

Compound type, Chemical name, CAS Number and molecular weight

Note: You are able to sort and find drugs according to compound type from drop-down menu in the application.


The Drug Profiles: Progress analysis and review of drug development.

MicroRNAs in Cancer Drug Pipeline Update provides you with a profile for each identified drug.
Click here for a short video (6m 12s) showing a typical drug profile

A typical drug profile reports on, depending on stage of development and available information:

Drug Name & SynonymsPresentation of drug name and synonyms.
Principal Company & Partners Presentation of principal Company and partners.
Target and Molecular Function of Target Described target(s) is/are presented with: Official Gene Symbol – Chromosome Location – Gene & Protein Name – Molecular Function
Target Localization Described target(s) is/are presented with primary and alternate localizations.
Target Expression Profiles
Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:
48 different normal tissue types
20 different types of cancer
47 cell lines
12 samples of primary blood cells
Mutation All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers.
Biological Structures The identity of available biological structures on drug targets was retrieved from the RCSB Protein Databank for you to easily review what available structures of drug targets exist.
Targeted Pathways Described target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, NCI-Nature and NetPath.
Mechanism Drug mechanism of action
Developmental Projects Summary field of developmental projects for the drug, including indication, developmental stage and status.
Example:
Cancer, myeloma – Phase II Clinical Trial – Active
Cancer, prostate – Phase III Clinical Trial – Ceased
Drug Description Short introduction to drug
Compound Data Compound type, Chemical name, CAS Number and molecular weight.
Patent Data Available patent information related to the drug is presented here.
Fillings and Approvals Approvals and submissions
Analyst comments
Deals and Licensing Collaborations and deals
Availability for licensing
Phase IV Data Available Phase IV development data, developmental history and scientific data.
Phase III Data Available Phase III development data, developmental history and scientific data.
Phase II Data Available Phase II development data, developmental history and scientific data.
Phase I Data Available Phase I development data, developmental history and scientific data.
Phase 0 Data Available Phase 0 development data, developmental history and scientific data.
Preclinical Data Available Preclinical data, developmental history and scientific data.
Discovery Data Available discovery development data, developmental history and scientific data., developmental history and scientific data.


About the unique Drug Pipeline Update Software Application

After purchase, the Drug Pipeline Update is delivered to you via electronic download in a powerful yet easy to use desktop application which requires no installation.

Find and sort drugs by twenty-four different parameters, all of which can be used as inclusion or exclusion parameters, plus free text search field. Our dynamic report generator lets you easily and quickly generate HTML drug profile reports directly in your web browser, whether it is a single drug profile or your own report of a selection of drugs that match your criteria.


Application Features Search, Find and Filter Panel with Initial Result Presentation
With this panel you can define your selectivity in each drug search with up to 24 different drug specific parameters. Each parameter has multi-select options to them and can be used as either an inclusion parameter or exclusion parameter.
Click here for a short video (2m 14s) showing an overview of the filters.

The initial result table is a dynamic sortable table which gives you a fast overview of found results and can be narrowed down further by your own additional keywords.
Click here for a short video (3m 26s) showing an example of an inclusion and exclusion search to create the initial results table.

Direct linkage from inside the application to related internet resources
- Drug data is linked to search engines like Google and PubMed
- Drug target data is linked directly to BioCarta, Human Protein Atlas, KEGG, NCI-Nature, NetPath etc.
- Direct links to company web pages of companies

Dynamic Report Generator
Our dynamic report generator lets you with ease and speed generate html reports directly in your web browser (Internet Explorer and FireFox), whether it is a single drug profile or an entire search you want have a report of.
Click here for a short video (6m12s) showing a typical drug profile

System Requirements - Operating system: Windows (2000/XP/Vista/7) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to MicroRNAs in Cancer Drug Pipeline Update.
    To find out more about MicroRNAs in Cancer Drug Pipeline Update, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that MicroRNAs in Cancer Drug Pipeline Update is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Drugs' category:


Oncology Drug Pipeline Update - Desktop App
Get desktop access to competitive drug information formore than 9,300 drugs across 200+ indications in oncology via our intuitive guided searches, innovative filters, and the result presented in smart reports. Learn More


T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 355 companies plus partners who are today developing 469 T cell receptor pathway targeting drugs in 1756 developmental projects in cancer across 242 different targets. In addition, there are 7 suspended drugs and another 210 drugs where development has been ceased. Learn More

Other selected research from the 'Drug Pipeline Updates' category:


Viral Carcinogenesis Drug Pipeline Update
BioSeeker Group have identified 246 companies plus partners who are today developing 311 viral carcinogenesis targeting drugs in 1170 developmental projects in cancer across 169 different targets. In addition, there is 1 suspended drug and another 138 drugs where development has been ceased. Learn More


T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 355 companies plus partners who are today developing 469 T cell receptor pathway targeting drugs in 1756 developmental projects in cancer across 242 different targets. In addition, there are 7 suspended drugs and another 210 drugs where development has been ceased. Learn More

Other selected research from the 'R&D' category:


HCV R&D and Business Development Database
This CD-ROM product is one of the most comprehensive and up to date information sources on chronic hepatitis C virus R&D and business development. Learn More


Interfering With the ECM-Receptor Interaction for the Treatment of Cancer Drug Pipeline Update
BioSeeker Group have identified 67 companies plus partners who are today developing 50 targeting ECM-receptor interaction drugs in 121 developmental projects in cancer across 52 different targets. In addition, there is 1 suspended drug and another 28 drugs where development has been ceased. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Colorectal Cancer, Melanoma and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Melanoma and by the mechanism/target/effect of Angiogenesis. Learn More


Complete Target Atlas in Oncology Drug Development: From Tumor to Targeted Therapy
This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer drugs. It will assist you in lead commercial analysis and product strategy thinking to build and nurture current and future portfolio of drug candidates and R&D alliances. Learn More

Other selected research from the 'Biologicals' category:


Proteins in Oncology Drug Pipeline Update
BioSeeker Group have identified 455 companies plus partners who are today developing 521 protein drugs in 914 developmental projects in cancer across 229 different targets. In addition, there are 2 suspended drugs and another 207 drugs where development has been ceased. Learn More


Cancer Peptides: From First-in-Class to Best-in-Class?
In-depth pipeline analytics of peptide drugs in oncology showing you where the Competition is, What is first-in-class and Is First-in-Class the Best-in-Class?, Indication expansion opportunities and much more Learn More